Injectable aqueous dispersions of propofol
Irritation upon injection of a formulation containing propofol is reduced or substantially eliminated by administering a stable, sterile, and antimicrobial aqueous dispersion comprising a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm consisting essentially of about 1% to about 15% of propofol, up to about 7% of a propofol-soluble diluent, and about 0.8% to about 4% of a surface stabilizing amphiphilic agent. The aqueous phase includes a pharmaceutically acceptable water-soluble polyhydroxy tonicity modifier. The propofol-containing dispersion is devoid of additional bactericidal or bacteriostatic preservative agents.
1. A composition comprising a stable, sterile, and injectable aqueous dispersion of a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm, the dispersion consisting essentially of
(a) between about 1% to about 15% of propofol;
(b) between about 1% to about 4% of a propofol soluble diluent selected from a medium chain triglyceride comprising medium chain fatty acids of synthetic or natural origin, or mixtures of said medium chain triglycerides;
(c) between about 0.5% to about 5% of one or more surface stabilizing amphiphilic agents; and
(d) from about 2.5% to about 20% of a pharmaceutically acceptable water-soluble polyhydroxy additive that acts as a tonicity modifier; and
(e) water;
wherein the ratio of propofol to diluent is about 1:4 to about 1:0.1 and the ratio of propofol to amphiphilic agent is about 1:0.8 to about 1:2.5, and the composition has a viscosity of greater than about 1.2 centipoise, and further wherein the dispersion inhibits microbial growth, is non-irritating at the site of injection and decreases hemolytic potential.
2. The composition according to claim 1 , wherein the surface stabilizing agent is a surface modifier selected from the group consisting of ionizable phospolipid, non-ionizable phospholipid, a mixture of ionizable phospholipid and cholesterol, a mixture of non-ionizable phospholipid and cholesterol, and mixtures thereof.
3. The composition according to claim 1 , wherein the propofol-soluble diluent is selected from the group consisting of a synthetic fatty acid triglyceride, a natural fatty acid triglyceride, and mixtures thereof.
4. The composition according to claim 1 , wherein the ratio of propofol to the propofol-soluble diluent is from about 1:3 to about 1:0.5.
5. The composition according to claim 1 , wherein the ratio of propofol to the propofol-soluble diluent is from about 1:2 to about 1:1.
6. The composition according to claim 1 , wherein the propofol-soluble diluent is a mixture of medium-chain triglycerides and vegetable oil.
7. The composition according to claim 6 , wherein the ratio of medium-chain triglyceride to vegetable oil is from 1:3 to 3:1.
8. The composition according to claim 1 , wherein the composition contains about 2% to about 10% of propofol.
9. The composition according to claim 1 , wherein the pharmaceutically acceptable water-soluble polyhydroxy additve provides the propofol-containing dispersion or composition with an osmolality of about 250 to about 700 milliosmolal.
10. The composition according to claim 9 , wherein the osmolality is about 300 to about 500 milliosmolal.
11. The composition according to claim 1 , wherein the viscosity is from about 2 to about 5 centipoise.
12. The composition according to claim 1 , wherein the propofol is present in an amount of about 2% to 5% by weight of the dispersion.
13. The composition according to claim 12 , wherein the propofol is present in an amount of about 2% by weight of the dispersion.
14. The composition according to claim 1 , wherein the polyhydroxy additive is mannitol.
15. The composition according to claim 14 , wherein mannitol is present in an amount of about 5.5% by weight of the dispersion.
16. The composition according to claim 1 , wherein the medium-chain triglyceride is present in an amount of 4% by weight of the dispersion.
17. The composition according to claim 1 , wherein the mixture of medium-chain triglycerides is present in an amount of 4% by weight of the dispersion.
18. The composition according to claim 1 , wherein the amphiphilic agent is egg lecithin.
19. The composition according to claim 18 , wherein the egg lecithin is present in an amount of about 1% to about 7% by weight of the dispersion.
20. The composition according to claim 19 , wherein the egg lecithin is present in an amount of about 1% to 3% by weight of the dispersion.
21. The composition according to claim 20 , wherein the egg lecithin is present in an amount of 1.6% by weight of the dispersion.
22. The composition according to claim 18 , wherein the egg lecithin contains not less than 98% phosphatidycholine.
23. The composition according to claim 1 , wherein the amphiphilic agent is anionic dimyristoylphosphatidyl glycerol.
24. The composition according to claim 1 , wherein the amphiphilic agent is selected from egg lecithin, which is present in an amount of 1.6% by weight of teh dispersion, anionic dimyristoylphosphatidyl glycerol, which is present in an amount of 0.1% by weight of teh dispersion, or a combination thereof.
25. The composition according to claim 1 , wherein the pH of the composition is about 4 to about 9.
26. The composition according to claim 25 , wherein the pH of the composition is about 5 to about 8.
27. The composition according to claim 1 , wherein the dispersion is sealed in a glass vial under nitrogen with a stopper.
28. The composition according to claim 1 , wherein the dispersion is sealed in a glass vial under an inert atmosphere with a stopper.
29. The composition according to claim 27 , wherein the dispersion is filled to about 70-90% volume capacity in the glass vial.
30. The composition according to claim 1 , wherein the dispersion is steam sterilizable.
31. A composition of a stable, sterile and injectable aqueous dispersion of a water-insoluble microdroplet matrix having a mean diameter of about 50 nm to about 1000 nm, the dispersion consisting essentially of:
(a) propofol in an amount of about 2% by weight of the dispersion;
(b) one or more medium-chain triglycerides in an amount of 4% by weight of the dispersion;
(c) egg lecithin in an amount of 1.6% by weight of the dispersion;
(d) anionic dimyristoylphosphatidyl glycerol in an amount of 0.1% by weight of the dispersion;
(e) mannitol in an amount of 5.5% by weight of the dispersion; and
(f) water.
32. The composition according to claim 31 , wherein the medium chain triglyceride is of synthetic or natural origin.
33. The composition according to claim 31 , wherein the dispersion is sealed in a glass vial under nitrogen with a stopper.
34. The composition according to claim 31 , wherein the dispersion is sealed in a glass vial under an inert atmosphere with a stopper.
35. The composition according to claim 33 , wherein the dispersion is filled to about 70-90% volume capacity in the glass vial.
36. The composition according to claim 31 , wherein the dispersion is steam sterilizable.
37. An injectable, stable, sterile, and antimicrobial aqueous dispersion comprising a water-insoluble microdroplet matrix having a mean diameter of about 50 nm to about 1000 nm capable of inhibiting the growth of microorganisms, the dispersion consisting essentially of:
propofol in an amount of about 2% by weight of the dispesion;
a medium-chain triglyceride in an amount of 4% by weight of the dispersion;
egg lecithin in an amount of 1.6% by weight of the dispersion;
anionic dimyristoylphosphatidyl glycerol in an amount of 0.1% by weight of the dispersion; and
mannitol in an amount 5.5% by weight of the dispersion;
wherein the dispersion is devoid of additional bactericidal or bacteriostatic preservative agents and causes no irritation at the site of injection.
38. An injectable, stable, sterile, and antimicrobial aqueous dispersion comprising a water-insoluble microdroplet matrix having a mean diameter of about 50 nm to about 1000 nm capable of inhibiting the growth of microorganisms, the dispersion consisting essentially of:
propofol in an amount of about 2% by weight of the dispesion;
a mixture of medium-chain triglyceride in an amount of 4% by weight of the dispersion;
egg lecithin in an amount of 1.6% by weight of the dispersion;
anionic dimyristoylphosphatidyl glycerol in an amount of 0.1% by weight of the dispersion; and
mannitol in an amount 5.5% by weight of the dispersion;
wherein the dispersion is devoid of additional bactericidal or bacteriostatic preservative agents and causes no irritation at the site of injection.
39. The dispersion according to claim 37 , wherein the medium chain triglyceride is of synthetic or natural origin.
40. The dispersion according to claim 37 , wherein the dispersion is sealed in a glass vial under nitrogen with a stopper.
41. The composition according to claim 37 , wherein the dispersion is sealed in a glass vial under an inert atmosphere with a stopper.
42. The dispersion according to claim 40 , wherein the dispersion is filled to about 70-90% volume capacity in the glass vial.
43. The composition according to claim 37 , wherein the dispersion is steam sterilizable.
44. A composition comprising a stable, sterile, and injectable aqueous dispersion of a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm, the dispersion consisting essentially of:
(a) propofol in an amount of from about 1% to about 15%;
(b) a liphophilic propofol-soluble diluent in an amount of about 4% or less;
(c) a surface stabilizing amphiphilic agent in an amount of between about 0.5% to about 5%;
(d) a pharmaceutically acceptable, water-soluble, polyhydroxy additive that acts as a tonicity modifier in an amount of from about 2.5% to about 20%; and
(e) water;
wherein the ration of propofol to the diluent is about 1:4 to about 1:0.1 and the ratio of propofol to the amphiphilic agent is about 1:0.8 to about 1:2.5, and the composition has a viscosity of greater than about 1.2 centipoise; and further wherein the dispersion inhibits microbial growth, is non-irritating at the site of injection and decreases hemolytic potential.
45. A composition comprising a stable, sterile, and injectable aqueous dispersion of a water-insoluble microdroplet matrix of mean diameter from about 50 nm to about 1000 nm, the dispersion consisting essentially of:
(a) propofol in an amount of from about 1% to about 2%;
(b) a liphophilic propofol-soluble diluent in an amount of about 4% or less;
(c) a surface stabilizing amphiphilic agent in an amount of between about 0.5% to about 5%;
(d) a pharmaceutically acceptable, water-soluble, polyhydroxy additive that acts as a tonicity modifier, said polyhydroxy additive present in the dispersion in an amount of about 2.5% to about 20%; and
(e) water;
wherein the ration of propofol to the diluent is about 1:4 to about 1:0.1 and the ratio of propofol to the amphiphilic agent is about 1:0.8 to about 1:2.5, and the composition has a viscosity of greater than about 1.2 centipoise; and further wherein the dispersion inhibits microbial growth, is non-irritating at the site of injection and decreases hemolytic potential.
46. The composition according to claim 44 , wherein the water-soluble, polyhydroxy additive is selected from mannitol, trehalose, glycerol, sucrose, dextrose, lactose, or mixtures thereo.
47. The composition according to claim 45 , wherein the water-soluble, polyhydroxy additives is selected from mannitol, trehalose, glycerol, sucrose, dextrose, lactose, or mixture thereof.
48. The composition according to claim 1 , wherein said composition prevents microbial growth, defined sa no more than 0.5 log increase from the initial inoculum, of each of Staphyloccus aureus, Eschrichia coli, Pseudomonas aeruginosa, Candida albicans , and Aspergillus niger for at least 7 days as measured by a test wherein a washed suspension of each said organism is added to a separate aliquot of said dispersion at approximately 1000 colony forming units per mL, at a temperaturein the range 20-35° C., whereafter said aliquots are incubated at 20-25 ° C. and are tested for viability of the microorganisms in the inoculated dispersion as determined by counting the colonies of said organism after 24, 48 and 7 days; and
results in no irritation at the site of injection as evidenced by a test wherein said dispersion is administered as a single daily bolus injection of 12.5 mg/kg, given on the basis of body weight, for 2 successive days over a period of approximately 30 seconds, in the caudal vein of a rat such that no visual increase in the diameter of the rat tail is noted after 48 hours post injection.
49. The composition according to claim 44 , wherein the propofol-soluble diluent is selected from the group consisting of saturated fatty acid esters, unsaturated fatty acid esters, esters of medium chain fatty acids of natural origin, esters of long chain fatty acids of natural origin, esters of medium chain fatty acids of synthetic origin, esters of long chain fatty acids of synthetic origin, triglycerides of medium chain fatty acids of natural origin, triglycerides of medium chain fatty acids of synthetic origin, triglycerides of long chain fatty acids of natural origin, triglycerides of long chain fatty acids of synthetic origin and mixtures thereof.
50. The composition according to claim 49 , wherein the propofol-soluble diluent is a pharmaceutically acceptable fish oil, or a mixture thereof.
51. The composition according to claim 44 , wherein the surface stabilizing amphiphilic agent is selected from the group consisting of charged phospholipids of natural origin, uncharged phospholipids of natural origin, synthetic phospholipids, pharmaceutically acceptable non-ionic surfactants, cholesterol and combinations thereof.
52. The composition according to claim 51 , wherein the surface stabilizing amphiphilic agent is selected from the group consisting of egg lecithin, soy lecithin, hydrogenated lecithin, phosphatidylcholines, phosphatidylglycerols, poloxamers, polaxamines, polyoxyethylene sorbitan esters and combination thereof.
53. The composition according to claim 45 , wherein the propofol-soluble diluent is selected from the group consisting of saturated fatty acid esters, unsaturated fatty acids esters, esters of medium chain fatty acids of natural origin, esters of long chain fatty acids of natural origin, esters of medium chain fatty acids of synthetic origin, esters of long chain fatty acids of synthetic origin, triglycerides of medium chain fatty acids of natural origin, triglycerides of medium chain fatty acids of synthetic origin, triglycerides of long chain fatty acids of natural origin, triglycerides of long chain fatty acids of synthetic origin and mixtures thereof.
54. The composition according to claim 53 , wherein the propofol-soluble diluent is a pharmaceutically acceptable vegetable oil, a pharmaceutically acceptable fish oil, or a mixture thereof.
55. The composition according to claim 45 , wherein the surface stabilizing amphiphilic agent is selected from the group consisting of charged phospholipids of natural origin, uncharged phospholipids of natural origin, synthetic phospholipids, pharmaceutically acceptable non-ionic surfactants, cholesterol and combinations thereof.
56. The composition according to claim 55 , wherein the surface stabilizing amphiphilic agent is selected from the group consisting of egg lecithin, soy lecithin, hydrogenated lecithin, phosphatidylcholines, phosphatidylglycerols, poloxamers, polaxamines, polyoxyethylene sorbitan esters and combinations thereof.